NCT04784910 - Study to Evaluate the Efficacy and Safety of DWP14012 in Prevention of NSAIDs Induced Peptic Ulcer | Biotech Hunter

Enrollment

423

Participants

Timeline

Start Date

May 21, 2021

Primary Completion Date

November 27, 2023

Study Completion Date

December 11, 2023

Conditions

Peptic Ulcer

Interventions

DRUG

DWP14012 20mg

DWP14012 20mg, tablet, orally, once daily for up to 24 weeks

DRUG

Lansoprazole 15 mg

Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks

DRUG

DWP14012 20mg placebo

DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks

DRUG

Lansoprazole 15 mg placebo

Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks

Trial Locations (1)

Asan Medical Center, Seoul